title: Effects of aspirin and celecoxib on rigidity in a rat model of Parkinson's disease.
abstract: Parkinson's disease (PD) is a degenerative neurodopaminergic disease in nigrostriatum pathway of human and is responsible for most of the movement disorders. Increasing evidence suggests that an inflammatory reaction accompanies the pathological processes caused by Cyclooxygenase (COX) seen in many neurodegenerative disorders, including PD and according to the recent researches chronic use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) decreases the risk of PD in human. In the study the rat left Substantia Nigra Pars Compacta (SNc) have been destroyed using electrical lesion (1 mA; DC; 8 Sec) to induce PD model. Then aspirin (30, 60 mg kg(-1)) and celecoxib (4, 8 mg kg(-1)) have been administrated orally to parkinsonian rats. When the animals were suffered to PD Murprogo's Method evaluated the rigidity ofparkinsonian rats. Both selective COX-2 inhibitor (celecoxib) and non-selective COX-2 inhibitor (aspirin) decreased the rigidity of parkinsonian rats p<0.05 but rigidity recovery after administration the selective COX-2 inhibitor was more than non-selective COX-2 inhibitor. These findings are additional pharmacological information which has suggested the use of NSAIDs as alternative way to treat the rigidity of PD.
authors.affiliation: Department of Physiology, School of Medicine and Physiology Research Center, Ahwaz Jondishapour University of Medical Sciences, Ahwaz, Iran.
authors.forename: Hadi Fathi
authors.initials: HF
authors.lastname: Moghaddam
authors.forename: Aliasghar
authors.initials: A
authors.lastname: Hemmati
authors.forename: Zahra
authors.initials: Z
authors.lastname: Nazari
authors.forename: Hasan
authors.initials: H
authors.lastname: Mehrab
authors.forename: Khosro M
authors.initials: KM
authors.lastname: Abid
authors.forename: Mehdi Shafiee
authors.initials: MS
authors.lastname: Ardestani
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology*; D000068579:Celecoxib; D051546:Cyclooxygenase 2 / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004195:Disease Models, Animal; D006801:Humans; D007249:Inflammation; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy*; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012306:Risk; D013449:Sulfonamides / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; D000068579:Celecoxib; D001241:Aspirin